-+ 0.00%
-+ 0.00%
-+ 0.00%

CVS Health (CVS) Could Be 35% Undervalued As Breakup Plan Reshapes The Story

Simply Wall St·11/21/2026 03:11:36
Listen to the news

CVS Health (CVS) has moved into the spotlight after announcing plans to split into two separate businesses by 2028. This structural shake-up could materially change how investors think about the healthcare giant.

Recent trading shows how sensitive CVS Health is to this kind of structural news. The 1 day share price return of 1.0% contrasts with a 7 day share price return down 9.5% and a 30 day move down 13.5%, while a 1 year total shareholder return of 6.8% and a 3 year total shareholder return of 30.4% point to a much stronger long-run experience for investors.

Review how investors are reacting to the CVS Health breakup news, then compare it with a curated group of quality companies on our 41 high quality undervalued stocks.

The breakup news has pushed CVS Health lower in the short term, while longer term returns still look positive on paper. Is most of the opportunity now reflected in the share price, or is there meaningful upside left as valuation comes into focus?

Most Popular Narrative: 35% Undervalued

On the latest view, the narrative fair value of CVS Health at $124 sits well above the last close of $80.84, which puts the breakup debate squarely against a valuation gap that the market has yet to close. According to Andrei_Niculescu, an investor in the Simply Wall St Community who wrote the narrative, that gap is tied less to day to day volatility and more to how investors weigh CVS Health’s earnings power against the structural risks of the split.

Management’s multi-year claim, first laid out at the December 2025 Investor Day, is mid-teens adjusted EPS CAGR through 2028. On the Q2 call they put a 2027 EPS floor of at least $8.44 (about 13% above a $7.46 “clean” 2026 baseline after stripping favorable prior-year development). No buybacks are assumed in 2026 while leverage comes down from approximately 3.5x.

See why 4 investors see CVS Health as 35% undervalued.

The narrative applies a 15.5x multiple to an adjusted 2026 earnings power of roughly $8.00 per share, which gives an estimated intrinsic value of $124. Set against the current market value of about $102.4b and analyst targets implying higher levels again, that assessment frames CVS Health as meaningfully undervalued on earnings and cash flow that are already visible in management guidance.

That view leans heavily on improving profitability. Recent figures show revenue of $418.2b, net income of $11.0b, and net profit margins of 2.6% compared with 0.1% a year earlier. Earnings over the past year have risen very sharply compared with the prior five year trend, while profit quality is flagged as high and cash generation has outpaced reported earnings.

The Simply Wall St DCF work points in the same direction. CVS Health is described as trading at 70.8% below the internal estimate of future cash flow value, with a DCF fair value of $276.51 per share versus the current $80.84. That gap, combined with a 9.4x P/E that is well under both peer and sector averages, suggests the market is applying a steep discount to the business even after accounting for the debt load and modest forecast revenue and earnings growth rates.

Investors weighing the breakup plan against these figures will likely want to watch three items closely. First, how management allocates debt and quantifies stranded costs between RemainCo and SpinCo. Second, whether forecast earnings growth in the low single digits annually still supports the fair value estimates as separation work ramps. Third, how the board balances capital returns, including a 3.29% dividend yield, with the priority to manage what is described as a high level of debt.

Result: Fair Value of $124 (UNDERVALUED)

Still, the CVS Health story can break if medical costs spike again and if separation expenses or stranded overhead prove heavier than the current narrative allows.

Find out about the key risks to this CVS Health narrative.

Next Steps

Mixed signals around CVS Health can feel confusing, so move quickly on your own homework and weigh both sides of the story. To see how the concerns and potential upsides line up, review the 5 key rewards and 1 important warning sign.

Looking for more investment ideas beyond CVS Health?

If you stop with CVS Health, you only see one angle. Cast a wider net and pressure test your thesis against other high quality opportunities.

  • Hunt for mispriced quality by scanning a curated 41 high quality undervalued stocks that filters for strong fundamentals and attractive valuations in one place.
  • Lock in income-focused opportunities by targeting companies in the 8 dividend fortresses that combine higher yields with disciplined payout profiles.
  • Strengthen your downside protection by using the 32 resilient stocks with low risk scores to highlight businesses with resilient balance sheets and lower overall risk scores.